Gan to kagaku ryoho. Cancer & chemotherapy
-
Gan To Kagaku Ryoho · Nov 2007
[The treatment strategy for type 4 gastric cancer with positive lavage cytology--a decision making of the therapeutic strategy by the change of the result of the lavage cytology].
It has been difficult to improve the prognosis of the type 4 advanced gastric cancer because the peritoneal dissemination develops frequently. In the present study, the therapeutic strategy, an administration of chemotherapy followed by gastrectomy, for the type 4 advanced gastric cancer with positive lavage cytology (CY) was discussed. ⋯ It may be important to perform re-staging laparoscopy with the evaluation of CY after preoperative chemotherapy for the type 4 advanced gastric cancer with positive CY, because the survival was comparatively better in cases with the change from positive CY to negative CY after the treatment. In conclusion, the treatment strategy for the type 4 advanced gastric cancer with positive CY was to administer chemotherapy followed by curative intent surgery for the case with negative CY after pre-operative treatment, while the other regimen of chemotherapy administration for the case with positive CY remained.
-
Gan To Kagaku Ryoho · Sep 2007
Case Reports[Successful desensitization using cisplatin after carboplatin-associated hypersensitivity reactions in 3 cases with recurrent ovarian carcinoma].
The standard chemotherapy for ovarian carcinoma is paclitaxel and carboplatin concomitant therapy. This combination is so frequently administered that a carboplatin-associated hypersensitivity reaction may occur after long-term treatment. ⋯ We report these cases that could be readministered platinum agent using the cisplatin desensitization method. This method was relatively safe and successful for patients with platinum-sensitive disease.
-
Gan To Kagaku Ryoho · Sep 2007
[Prophylactic effect of tropisetron hydrochloride against nausea and vomiting in patients receiving chemotherapy for hematological malignancies].
To establish the effectiveness of oral 5-HT(3) antagonist, oral 5 mg tropisetron was introduced in the 21 cases with hematological malignancies for the prevention of chemotherapy-induced nausea and vomiting. Nausea and vomiting did not develop in 81% of patients receiving the tropisetron in this study. ⋯ In conclusion, tropisetron is effective for the prevention of chemotherapy-induced nausea and vomiting in treatment for hematological malignancies. It is suitable as first-line therapy for outpatients.
-
Gan To Kagaku Ryoho · Sep 2007
[Pharmacokinetics of controlled-release oxycodone in patients with cancer pain].
Oxycodone is a useful analgesic for cancer patients in pain. However, its pharmacokinetics have not been sufficiently examined and there is a lack of information, with very few reports on pharmacokinetics concerning the absorption process in particular. With this in mind, we studied the pharmacokinetics of controlled-release oxycodone (Oxy contin). ⋯ In addition, the serum oxycodone concentration hardly rose until 1 hour after and just before medication, whereupon a rapid increase was evident after 1 hour. The pharmacokinetics of controlled-release oxycodone in patients with cancer pain were clarified in this study. Especially during the absorption process, the lag time was calculated specifically at about 1 hour, making it approximately equal to MS contin.
-
Trastuzumab is a recombinant humanized monoclonal antibody directed against HER2. Several issues about its optimal use,mechanism of action or resistance still await convincing answers. Results of large-scale randomized trials and preclinical study might answer these questions. This review summarizes current knowledge about trastuzumab treatment.